CYP2C19-话题@MedSci - 梅斯（MedSci）

#CYP2C19#

8篇内容 | 1174人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1933939, encodeId=4e3e193393951, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=JAMA NEURO/天坛王拥军团队：CYP2C19功能缺失等位基因的急性中风或TIA患者使用替格瑞洛和阿司匹林的益处和风险, objectType=article, longId=730490, objectId=88ade30490b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ade30490b1, replyNumber=0, likeNumber=104, createdTime=2023-04-15, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ade30490b1, moduleTitle=JAMA NEURO/天坛王拥军团队：CYP2C19功能缺失等位基因的急性中风或TIA患者使用替格瑞洛和阿司匹林的益处和风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=88ade30490b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933938, encodeId=6ae71933938bb, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=NEJM：CYP2C19功能缺失携带者服用替格瑞洛与氯吡格雷对卒中或TIA的比较分析, objectType=article, longId=293164, objectId=310429316466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=310429316466, replyNumber=0, likeNumber=79, createdTime=2022-06-10, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=310429316466, moduleTitle=NEJM：CYP2C19功能缺失携带者服用替格瑞洛与氯吡格雷对卒中或TIA的比较分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=310429316466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933937, encodeId=e527193393e88, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=Eur J Clin Pharmacol：不同CYP2C19等位基因的患者，每天两次的雷贝拉唑半剂量对酸抑制的影响, objectType=article, longId=214795, objectId=32f8214e959f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32f8214e959f, replyNumber=0, likeNumber=72, createdTime=2021-11-17, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32f8214e959f, moduleTitle=Eur J Clin Pharmacol：不同CYP2C19等位基因的患者，每天两次的雷贝拉唑半剂量对酸抑制的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=32f8214e959f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=JAMA：CYP2C19Lof携带患者与基因型指导的抗血小板药物治疗策略, objectType=article, longId=199944, objectId=236e199944ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236e199944ce, replyNumber=0, likeNumber=102, createdTime=2020-11-02, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236e199944ce, moduleTitle=JAMA：CYP2C19Lof携带患者与基因型指导的抗血小板药物治疗策略, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=236e199944ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933935, encodeId=def1193393577, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=CYP2C19基因型指导的抗血小板治疗可能是有益的, objectType=article, longId=118794, objectId=b4e1118e9497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4e1118e9497, replyNumber=0, likeNumber=76, createdTime=2018-07-09, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4e1118e9497, moduleTitle=CYP2C19基因型指导的抗血小板治疗可能是有益的, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b4e1118e9497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933934, encodeId=4fc81933934eb, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=CLIN PHARMACOKINET：抗逆转录病毒药物和CYP2C9 / CYP2C19多态性对Etravirine药代动力学的影响？, objectType=article, longId=100535, objectId=2246100535ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2246100535ac, replyNumber=0, likeNumber=92, createdTime=2018-03-09, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2246100535ac, moduleTitle=CLIN PHARMACOKINET：抗逆转录病毒药物和CYP2C9 / CYP2C19多态性对Etravirine药代动力学的影响？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2246100535ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933933, encodeId=1b361933933d7, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=NEJM：CYP2C19基因型对氯吡格雷治疗转归的影响, objectType=article, longId=2227, objectId=1953222ed2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1953222ed2, replyNumber=0, likeNumber=76, createdTime=2011-06-05, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1953222ed2, moduleTitle=NEJM：CYP2C19基因型对氯吡格雷治疗转归的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1953222ed2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933932, encodeId=964119339325b, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, objectTitle=柳叶刀：CYP2C19和ABCB1多态性对三种格雷类药物用于急性冠脉综合征的比较, objectType=article, longId=2203, objectId=04842203c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04842203c5, replyNumber=0, likeNumber=66, createdTime=2011-03-10, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04842203c5, moduleTitle=柳叶刀：CYP2C19和ABCB1多态性对三种格雷类药物用于急性冠脉综合征的比较, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=04842203c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CYP2C19

2020-05-29

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

JAMA NEURO/天坛王拥军团队：CYP2C19功能缺失等位基因的急性中风或TIA患者使用替格瑞洛和阿司匹林的益处和风险

2023-04-15

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

NEJM：CYP2C19功能缺失携带者服用替格瑞洛与氯吡格雷对卒中或TIA的比较分析

2022-06-10

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

Eur J Clin Pharmacol：不同CYP2C19等位基因的患者，每天两次的雷贝拉唑半剂量对酸抑制的影响

2021-11-17

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

JAMA：CYP2C19Lof携带患者与基因型指导的抗血小板药物治疗策略

2020-11-02

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

CYP2C19基因型指导的抗血小板治疗可能是有益的

2018-07-09

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

CLIN PHARMACOKINET：抗逆转录病毒药物和CYP2C9 / CYP2C19多态性对Etravirine药代动力学的影响？

2018-03-09

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

NEJM：CYP2C19基因型对氯吡格雷治疗转归的影响

2011-06-05

30397604 (审核中...)

前往app查看评论内容

#CYP2C19#

柳叶刀：CYP2C19和ABCB1多态性对三种格雷类药物用于急性冠脉综合征的比较

2011-03-10

科室
- - 订阅+
  - 更多科室
工具
服务